Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Treatment of Recurrent Stage IV High Risk Neuroblastoma With Sintilimab

NCT04412408 is registered in ClinicalTrials.gov with Shanghai Children's Medical Center as lead sponsor.

NCT NCT04412408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Treatment of Recurrent Stage IV High Risk Neuroblastoma With Sintilimab
Lead sponsor
Shanghai Children's Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
September 1, 2020
Completion date
June 30, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent stage iv high risk neuroblastoma